STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (VIR) pioneers immunology solutions targeting complex infectious diseases through innovative platforms including antibody therapies, T cell engineering, and siRNA technology. This dedicated news hub provides investors and industry stakeholders with timely updates on clinical developments, strategic partnerships, and regulatory milestones.

Access authoritative updates on VIR's research pipeline, financial performance announcements, and scientific breakthroughs in infectious disease management. Our curated collection ensures transparent access to press releases spanning clinical trial progress, collaborative initiatives, and patent filings.

Key updates include advancements in hepatitis B/HIV therapies, influenza A research, and platform technology licensing agreements. Bookmark this page to efficiently monitor VIR's contributions to biotechnology and its evolving position in global health innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Vir Biotechnology announces new data from its hepatitis B and D virus (HBV and HDV) portfolio presented at the EASL Congress. The data show promising results for the combination of an antiviral with an immunomodulator in achieving HBsAg loss and higher cure rates. Preclinical data also suggest the potential of VIR-2218 and VIR-3434 for the treatment of HDV infection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
management
-
Rhea-AI Summary
Vir Biotechnology provided a corporate update and reported financial results for Q1 2023. Multiple data readouts are anticipated in 2023 from ongoing Phase 2 programs in hepatitis B and D, and influenza. The CEO is optimistic about the near-term catalysts and the strength of the pipeline and balance sheet. The company has $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
Rhea-AI Summary
Vir Biotechnology receives $10 million grant from the Bill & Melinda Gates Foundation to support the development of an investigational HIV T cell vaccine. The grant will fund the Phase 1 clinical development of VIR-1388, a novel T cell vaccine designed to create a safe and effective HIV vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
Vir Biotechnology, Inc.

OTC:VIR

VIR Rankings

VIR Stock Data

759.35M
101.72M
12.01%
76.71%
5.66%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN FRANCISCO